Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II second-line FOLFIRI plus ramucirumab in RAS wild-type unresectable advanced or recurrent colorectal cancer
jRCTs061180002Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, fluorouracil, folinic acid and ramucirumab in colorectal cancer (CRC), sponsored by Eli Lilly and Company. Primary endpoint: 6-month progression-free survival rate. Started Nov 2018; status: completed.
02
Drugs
irinotecanfluorouracilfolinic acidramucirumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs061180002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180002.